Published in Virol J on June 02, 2008
Papillomavirus E6 oncoproteins. Virology (2013) 1.21
Small molecule inhibitors of human papillomavirus protein - protein interactions. Open Virol J (2011) 0.97
Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. Virology (2013) 0.85
Degradation of Human PDZ-Proteins by Human Alphapapillomaviruses Represents an Evolutionary Adaptation to a Novel Cellular Niche. PLoS Pathog (2015) 0.78
Dense genotyping of immune-related loci identifies variants associated with clearance of HPV among HIV-positive women in the HIV epidemiology research study (HERS). PLoS One (2014) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer (2003) 8.01
Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol (1998) 3.99
PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane. J Clin Invest (1999) 2.67
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65
Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene (1999) 2.25
Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J Biol Chem (2000) 2.09
Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol (2000) 1.97
Making protein interactions druggable: targeting PDZ domains. Nat Rev Drug Discov (2004) 1.73
Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene (2002) 1.71
Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J (2004) 1.61
Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci (2008) 1.59
MAGUKs in synapse assembly and function: an emerging view. Cell Mol Life Sci (2004) 1.54
Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein. J Virol (2007) 1.34
The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins. J Biol Chem (2006) 1.23
Synaptic scaffolding molecule is involved in the synaptic clustering of neuroligin. Mol Cell Neurosci (2004) 1.21
HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene (2007) 1.21
HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation. Oncogene (2004) 1.20
Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential. Cancer Res (2005) 1.15
MAGI-1: a widely expressed, alternatively spliced tight junction protein. Exp Cell Res (2002) 1.08
Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene (2007) 1.08
Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix. J Infect Dis (2006) 1.07
HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP. Oncogene (2006) 1.00
Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. J Gen Virol (2004) 0.89
Functional analysis of the guanylate kinase-like domain in the synapse-associated protein SAP97. Eur J Biochem (1998) 0.89
Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53. J Virol (2005) 0.88
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
The biology and life-cycle of human papillomaviruses. Vaccine (2012) 2.53
p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer (2004) 2.18
Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol (2004) 2.01
Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene (2002) 1.71
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis (2011) 1.64
Human discs large and scrib are localized at the same regions in colon mucosa and changes in their expression patterns are correlated with loss of tissue architecture during malignant progression. Int J Cancer (2006) 1.50
Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. J Biol Chem (2003) 1.42
The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene (2005) 1.40
Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene (2003) 1.36
Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein. J Virol (2007) 1.34
Viruses and the 26S proteasome: hacking into destruction. Trends Biochem Sci (2003) 1.32
Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J Cell Sci (2003) 1.31
Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene (2005) 1.25
Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol (2010) 1.25
Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. Traffic (2012) 1.23
Determinants for the development of visceral leishmaniasis disease. PLoS Pathog (2013) 1.22
HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation. Oncogene (2004) 1.20
Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun (2003) 1.20
Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol (2010) 1.19
Control of alpha subunit of eukaryotic translation initiation factor 2 (eIF2 alpha) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2 alpha-dependent gene expression and cell death. Mol Cell Biol (2004) 1.18
Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun (2008) 1.13
Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis (2011) 1.13
Changes in expression of the human homologue of the Drosophila discs large tumour suppressor protein in high-grade premalignant cervical neoplasias. Carcinogenesis (2002) 1.12
Comparative analysis of the intracellular location of the high- and low-risk human papillomavirus oncoproteins. Virology (2002) 1.11
Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator. J Virol (2006) 1.11
Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS (2010) 1.11
Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix. J Infect Dis (2006) 1.07
Development of a genetic assay to distinguish between Leishmania viannia species on the basis of isoenzyme differences. Clin Infect Dis (2006) 1.06
Comparison of the effects of Leishmania major or Leishmania donovani infection on macrophage gene expression. Infect Immun (2007) 1.04
PDZ domains: the building blocks regulating tumorigenesis. Biochem J (2011) 1.04
Regulation of the discs large tumor suppressor by a phosphorylation-dependent interaction with the beta-TrCP ubiquitin ligase receptor. J Biol Chem (2003) 1.04
Human papillomaviruses and the specificity of PDZ domain targeting. FEBS J (2012) 1.04
Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen. Diagn Microbiol Infect Dis (2002) 1.03
Differential expression of the human homologue of drosophila discs large oncosuppressor in histologic samples from human papillomavirus-associated lesions as a marker for progression to malignancy. Int J Cancer (2004) 1.03
Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance. Virology (2011) 1.02
Analysis of specificity determinants in the interactions of different HPV E6 proteins with their PDZ domain-containing substrates. Virology (2008) 1.02
Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array using HPV52-specific TaqMan E6/E7 quantitative real-time PCR. J Virol Methods (2008) 1.01
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis (2009) 1.01
HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis (2007) 1.01
Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis (2007) 1.00
HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation. EMBO J (2012) 1.00
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol (2011) 0.99
Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. J Gen Virol (2004) 0.99
SNX17 facilitates infection with diverse papillomavirus types. J Virol (2012) 0.98
Repair of a minimal DNA double-strand break by NHEJ requires DNA-PKcs and is controlled by the ATM/ATR checkpoint. Nucleic Acids Res (2003) 0.98
The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology (2009) 0.98
Intracellular eukaryotic parasites have a distinct unfolded protein response. PLoS One (2011) 0.98
Reducing visceral leishmaniasis by insecticide impregnation of bed-nets, Bangladesh. Emerg Infect Dis (2013) 0.97
Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine (2013) 0.96
Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein. Oncogene (2005) 0.96
Screening Leishmania donovani-specific genes required for visceral infection. Mol Microbiol (2010) 0.96
High-risk human papillomavirus E6 oncoproteins interact with 14-3-3ζ in a PDZ binding motif-dependent manner. J Virol (2012) 0.96
Redistribution of the discs large tumor suppressor protein during mitosis. Exp Cell Res (2003) 0.95
The role of protein kinase A regulation of the E6 PDZ-binding domain during the differentiation-dependent life cycle of human papillomavirus type 18. J Virol (2013) 0.94
HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures. Oncogene (2004) 0.94
Cloning and functional analysis of the promoter region of the human Disc large gene. Gene (2008) 0.94
Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. J Mol Biol (2004) 0.93
Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J Virol (2011) 0.92
Chimaeric HPV E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins. Oncogene (2002) 0.92
The human papillomavirus (HPV) E6* proteins from high-risk, mucosal HPVs can direct degradation of cellular proteins in the absence of full-length E6 protein. J Virol (2009) 0.92
Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol (2012) 0.92
The invasive capacity of HPV transformed cells requires the hDlg-dependent enhancement of SGEF/RhoG activity. PLoS Pathog (2012) 0.92
Skip interacts with the retinoblastoma tumor suppressor and inhibits its transcriptional repression activity. Nucleic Acids Res (2002) 0.91
Analysis of the PDZ binding specificities of Influenza A virus NS1 proteins. Virol J (2011) 0.91
Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein. Mol Microbiol (2010) 0.91
Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations. Int J Cancer (2012) 0.91
A FRET-based real-time PCR assay to identify the main causal agents of New World tegumentary leishmaniasis. PLoS Negl Trop Dis (2013) 0.91
Mutational analysis of the discs large tumour suppressor identifies domains responsible for human papillomavirus type 18 E6-mediated degradation. J Gen Virol (2002) 0.91
Human tumour viruses and the deregulation of cell polarity in cancer. Nat Rev Cancer (2012) 0.90
Modification of human papillomavirus minor capsid protein L2 by sumoylation. J Virol (2010) 0.90
Involvement of the Leishmania donovani virulence factor A2 in protection against heat and oxidative stress. Exp Parasitol (2012) 0.90
E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1. J Virol (2011) 0.90
The Mdm2 ubiquitin ligase enhances transcriptional activity of human papillomavirus E2. J Virol (2008) 0.89
The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detect Prev (2005) 0.89
Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. J Gen Virol (2004) 0.89
Leishmania donovani zymodeme MON-37 isolated from an autochthonous visceral leishmaniasis patient in Sri Lanka. Pathog Glob Health (2012) 0.89
Identification and characterization of a protein-tyrosine phosphatase in Leishmania: Involvement in virulence. J Biol Chem (2006) 0.89
Systematic analysis of the amino acid residues of human papillomavirus type 16 E7 conserved region 3 involved in dimerization and transformation. J Virol (2011) 0.89
Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccin (2011) 0.88
Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53. J Virol (2005) 0.88
Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis. Vaccine (2012) 0.88
The high-risk HPV E6 oncoprotein preferentially targets phosphorylated nuclear forms of hDlg. Virology (2009) 0.87
Regulation of the hDlg/hScrib/Hugl-1 tumour suppressor complex. Exp Cell Res (2008) 0.87
Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor. J Virol (2012) 0.87
HPV-18 E6*I modulates HPV-18 full-length E6 functions in a cell cycle dependent manner. Int J Cancer (2004) 0.87
Cleavage of MAGI-1, a tight junction PDZ protein, by caspases is an important step for cell-cell detachment in apoptosis. Apoptosis (2007) 0.86